Q Fever Market Outlook:
Q Fever Market size was valued at USD 943 million in 2024 and is projected to reach USD 5.50 billion by the end of 2034, rising at a CAGR of 4.6% during the forecast period, i.e., 2025-2034. In 2025, the industry size of Q fever is evaluated at USD 985 million.
In 2023, the CDC in the U.S. reported 177 acute Q fever cases and 33 chronic cases. Passive surveillance permitted the documentation of a total of 1,108 acute and 271 chronic cases in the U.S. Globally, Q fever continues to be endemic in the presence of ruminants, including cattle, sheep, and goats. Whereas, human outbreaks occasionally occur in excess of 3,000 cases. This suggests a global population of symptomatic patients potentially in the tens of thousands annually.
The supply chain for Q fever-related products includes active pharmaceutical ingredients (APIs), primarily doxycycline and hydroxychloroquine, diagnostic kits, and medical devices. These components originate from pharmaceutical API manufacturers, laboratories producing test kits, and device manufacturers that specialize in assembling these devices. No broad Producer Price Index (PPI) and Consumer Price Index (CPI) data were readily available for Q fever products. Recent reports from the U.S. Bureau of Labor Statistics indicated an annual price increase for APIs of 1–3.
Import/export data from the WOAH (World Organization for Animal Health) shows countries with significant livestock industries export veterinary vaccines and test kits on a regular basis. Cattle, sheep, and goat birthing materials. This represents a trade risk as well as a latent supply opportunity.
